We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

PSMA PET Imaging Set to Become New Standard of Care for Detecting Prostate Cancer Metastases

By MedImaging International staff writers
Posted on 18 Feb 2022
Print article
Image: PSMA-Targeted Therapy in Prostate Cancer (Photo courtesy of Pexels)
Image: PSMA-Targeted Therapy in Prostate Cancer (Photo courtesy of Pexels)

PSMA PET imaging will soon become the new standard of care for detecting prostate cancer metastases, leading to improved care for these patients.

These are the latest findings of the Cleveland Clinic (Cleveland, OH, USA) which has ranked PSMA PET imaging at No. 2 on its list of the top 10 medical innovations to watch in 2022.

With a one in eight chance of diagnosis, prostate cancer is an ever-present worry for men. While many patients survive the disease, some develop metastatic cancer, which can lead to a poor outcome and possibly death. Early detection and imaging using CT and MRI scans are critical for staging and tumor location, but offer limited accuracy. Now, a promising new imaging technology has emerged, called prostate-specific membrane antigen positron emission tomography, or PSMA PET.

PSMA is an antigen found in high levels on the surface of prostate cancer cells and is a potential biomarker for disease. PSMA PET uses a radioactive tracer to locate and attach to PSMA proteins, which are then visible by PET. This targeted approach can be used in conjunction with CT or MRI scans to visualize where prostate cancer cells are residing. Results during phase three clinical trials showed substantially increased accuracy for detection of prostate metastasis compared to conventional imaging. FDA approved in 2021, experts say the PET tracer procedure will soon become the new standard of care for detecting prostate cancer metastasis, leading to improved care for these patients.

Related Links:
Cleveland Clinic 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ceiling-Mounted Digital Radiography System
Radiography 5000 C
New
CT Phantom
CIRS Model 610 AAPM CT Performance Phantom
Ultrasound System
Acclarix AX9

Print article

Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Whole-body maximum-intensity projections over time after [68Ga]Ga-DPI-4452 administration (Photo courtesy of SNMMI)

New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients

Clear cell renal cell cancer (ccRCC) represents 70-80% of renal cell carcinoma cases. While localized disease can be effectively treated with surgery and ablative therapies, one-third of patients either... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more